AAAAAA

   
Results: 1-8 |
Results: 8
Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy
Authors: Huang, W De Gruttola, V Fischl, M Hammer, S Richman, D Havlir, D Gulick, R Squires, K Mellors, J
Citation: W. Huang et al., Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy, J INFEC DIS, 183(10), 2001, pp. 1455-1465
Amprenavir in combination with lamivudine and zidovudine versus lamivudineand zidovudine alone in HIV-1-infected antiretroviral-naive adults
Authors: Goodgame, JC Pottage, JC Jablonowski, H Hardy, WD Stein, A Fischl, M Morrow, P Feinberg, J Brothers, CH Vafidis, I Nacci, P Yeo, J Pedneault, L
Citation: Jc. Goodgame et al., Amprenavir in combination with lamivudine and zidovudine versus lamivudineand zidovudine alone in HIV-1-infected antiretroviral-naive adults, ANTIVIR TH, 5(3), 2000, pp. 215-225
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis
Authors: Babiker, A Bartlett, J Breckenridge, A Collins, G Coombs, R Cooper, D Creagh, T Cross, A Daniels, M Darbyshire, J Dawson, D DeGruttola, V DeMasi, R Dolin, R Eron, J Fischl, M Grossberg, S Hamilton, J Hammer, S Hartigan, P Henry, K Hill, A Hughes, M Kahn, J Katlama, C Katzenstein, D Kim, S Mildvan, D Montaner, J Moore, M Neaton, J O'Brien, W Ribaudo, H Richman, D Saag, M Salgo, M Saravolatz, L Schooley, R Seligmann, M Staszewski, S Struthers, L Tierney, C Tsiatis, A Welles, S
Citation: A. Babiker et al., Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis, AIDS RES H, 16(12), 2000, pp. 1123-1133
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884
Authors: Fletcher, CV Acosta, EP Cheng, HL Haubrich, R Fischl, M Raasch, R Mills, C Hu, XJ Katzenstein, D Remmel, RP Gulick, RM
Citation: Cv. Fletcher et al., Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884, AIDS, 14(16), 2000, pp. 2495-2501
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359
Authors: Gulick, RM Hu, XJ Fiscus, SA Fletcher, CV Haubrich, R Cheng, HL Acosta, E Lagakos, SW Swanstrom, R Freimuth, W Snyder, S Mills, C Fischl, M Pettinelli, C Katzenstein, D
Citation: Rm. Gulick et al., Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359, J INFEC DIS, 182(5), 2000, pp. 1375-1384
Efficacy and safety of delavirdine mesylate with zidovudine and didanosinecompared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm(3) (ACTG 261)
Authors: Friedland, GH Pollard, R Griffith, B Hughes, M Morse, G Bassett, R Freimuth, W Demeter, L Connick, E Nevin, T Hirsch, M Fischl, M
Citation: Gh. Friedland et al., Efficacy and safety of delavirdine mesylate with zidovudine and didanosinecompared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm(3) (ACTG 261), J ACQ IMM D, 21(4), 1999, pp. 281-292
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence
Authors: Abrams, D Allan, D Antunes, F Breckenridge, A Bruun, J Cameron, W Carbon, C Chalmers, I Chang, H Chodakewitz, J Clendenin, N Clumeck, N Collier, A Collins, G Cooper, E Cooper, D Danner, S D'Aquila, R DeGruttola, V DeMasi, R Dee, L Deyton, L Dixon, D Farthing, C Feinberg, J Fischl, M Flepp, M Gartland, M Gatell, J Gazzard, B Goebel, F Gotzsche, P Gringeri, A Hall, D Hamilton, J Hammer, S Hartigan, P Heath-Chiozzi, M Henry, K Hill, A Hirschel, B Ioannidis, J Kahn, J Katlama, C Katzenstein, D Killen, J King, E de Loes, SK Kravcik, S Lange, J Leavitt, R Leonard, J Maeland, A Mannucci, P Mathiesen, L McDade, H Meibohn, A Melander, H Merigan, T Mulder, J Myers, M Neaton, J Nessling, M Perrin, L Pettinelli, C Phair, J Phillips, A Pinching, A Poppa, A Power, L Reiss, P Richman, D Rooney, J Rousseau, F Rutherford, G Salgo, M Sandstrom, E Saravolatz, L Savidge, G Schnittman, S Schooley, R Seligmann, M Simberkoff, M Skowron, G Slade, P Smith, D Smith, RP Soriano, V Stanley, K Stingl, G Stoffels, P Struthers, L Tierney, C Thompson, M Van der Broeck, R Van Leeuven, R Van Weverling, G Veenstra, J Vella, S Volberding, P Weber, J Winslow, D Yeni, P Yeo, J Dormont, J Sande, M Weller, I Babiker, A Collins, R Darbyshire, J Duncan, W Foulkes, M Hughes, M Peto, R Peto, T Walker, S
Citation: D. Abrams et al., Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence, LANCET, 353(9169), 1999, pp. 2014-2025
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy
Authors: Para, MF Meehan, P Holden-Wiltse, J Fischl, M Morse, G Shafer, R Demeter, LM Wood, K Nevin, T Virani-Ketter, N Freimuth, WW
Citation: Mf. Para et al., ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy, ANTIM AG CH, 43(6), 1999, pp. 1373-1378
Risultati: 1-8 |